Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07370454 · ClinicalTrials.gov registry record
Xpert® Hemorrhagic Fever on the GeneXpert® Edge X System
A clinical trial of Hemorrhagic Fever, sponsored by Cepheid.
- Completed
- Registry status
- 408
- Enrollment target
- 1
- Study location
NCT07370454: Completed study of Hemorrhagic Fever, sponsored by Cepheid.
NCT07370454 is a study of Hemorrhagic Fever that has completed, run by Cepheid. The registered enrollment target is 408 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07370454, a study of Hemorrhagic Fever, has completed, sponsored by Cepheid.
- COMPLETED
- Registry status
- 408 participants
- Enrollment target
- 1
- Study location
Study Summary
A multi-site observation study that was conducted a geographically diverse sites across the United States
Primary Outcome
Xpert test compared to expected status
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Xpert Hemorrhagic Fever test
Study Locations (1)
Maryland
- USAMRIID - Frederick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2025-10-03 |
What the finished NCT07370454 record still lists
NCT07370454 is an observational study that tracks outcomes without assigning an intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Hemorrhagic Fever appearing as the primary indexed condition, and to 1 intervention - of which Xpert Hemorrhagic Fever test is the first listed.
NCT07370454 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07370454 about?
NCT07370454 is a clinical study titled "Xpert® Hemorrhagic Fever on the GeneXpert® Edge X System". A multi-site observation study that was conducted a geographically diverse sites across the United States
What is the current status of trial NCT07370454?
This trial is currently completed. The enrollment target is 408 participants. The study started on 2025-01-13. Estimated completion is 2025-10-03.
What conditions does trial NCT07370454 study?
This clinical trial studies the following conditions: Hemorrhagic Fever.
What interventions are being tested in trial NCT07370454?
The interventions under investigation include: Xpert Hemorrhagic Fever test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07370454?
This trial is sponsored by Cepheid, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07370454 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06612268 · 408 participants · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI